GlassScriptPhysician profile
Kameron David Mullaney
NPI 1225656085
$733.22
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $279 · 2022: $454.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $113.03 | 2021-2022 | |
| Mylan Specialty L.P. | $109.58 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.76 | 2021-2022 | |
| Lilly USA, LLC | $76.58 | 2021-2022 | |
| Glaxosmithkline, LLC. | $58.32 | 2022 | |
| Pfizer INC. | $56.46 | 2021-2022 | |
| Shield Therapeutics INC | $37.83 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $37.67 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $32.74 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $29.08 | 2022 | |
| Novo Nordisk INC | $27.64 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.11 | 2022 | |
| Sanofi Pasteur INC. | $17.21 | 2021 | |
| Amgen INC. | $14.21 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kameron Mullaney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.